Cargando…

An Overview of Therapeutic Options in Relapsing-remitting Multiple Sclerosis

Multiple sclerosis (MS) is a chronic disorder of the central nervous system (CNS). MS affects 2.1 million individuals every year and is also considered a major cause of economic health burden around the world. Genetics and environmental factors both play a role in the pathogenesis of MS by activatin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saleem, Sidra, Anwar, Arsalan, Fayyaz, Muniba, Anwer, Fatima, Anwar, Faria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2019
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759037/ https://www.ncbi.nlm.nih.gov/pubmed/31565644 http://dx.doi.org/10.7759/cureus.5246

Ejemplares similares

Recent Advances and Therapeutic Options in Lambert-Eaton Myasthenic Syndrome
por: Anwar, Arsalan, et al.
Publicado: (2019)

Balance Changes in Patients With Relapsing-Remitting Multiple Sclerosis: A Pilot Study Comparing the Dynamics of the Relapse and Remitting Phases
por: Findling, Oliver, et al.
Publicado: (2018)

Effect of Seasonal Variation on Relapse Rate in Patients With Relapsing-Remitting Multiple Sclerosis in Saudi Arabia
por: Makkawi, Seraj, et al.
Publicado: (2022)

Impact of the McDonald Criteria 2017 on Early Diagnosis of Relapsing-Remitting Multiple Sclerosis
por: Schwenkenbecher, Philipp, et al.
Publicado: (2019)

Cognitive and Language Deficits in Multiple Sclerosis: Comparison of Relapsing Remitting and Secondary Progressive Subtypes
por: Ntoskou, Katerina, et al.
Publicado: (2018)

Natural Variation of Vitamin D and Neurofilament Light Chain in Relapsing-Remitting Multiple Sclerosis
por: Røsjø, Egil, et al.
Publicado: (2020)

Probing Context-Dependent Modulations of Ipsilateral Premotor-Motor Connectivity in Relapsing-Remitting Multiple Sclerosis
por: Ruiu, Elisa, et al.
Publicado: (2020)

Memory Impairment in Relapsing-Remitting Multiple Sclerosis Using a Challenging Semantic Interference Task
por: Matias-Guiu, Jordi A., et al.
Publicado: (2020)

Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis
por: Alroughani, Raed, et al.
Publicado: (2021)

Vaginal Herpes Zoster While Under Treatment for Relapsing-Remitting Multiple Sclerosis With Diroximel Fumarate
por: Gül, Sedat, et al.
Publicado: (2023)

Analysis of the Group of Pediatric Patients With Relapsing-Remitting Multiple Sclerosis: Data From the Czech National Registry
por: Vališ, Martin, et al.
Publicado: (2022)

Case Report: Baló's Concentric Sclerosis-Like Lesion in a Patient With Relapsing-Remitting Multiple Sclerosis Treated With Dimethyl Fumarate
por: Kania, Karolina, et al.
Publicado: (2022)

Periventricular Hyperintensities Mimicking Multiple Sclerosis
por: Saleem, Sidra, et al.
Publicado: (2019)

Relapsing-Remitting Multiple Sclerosis Is Associated With Regional Brain Activity Deficits in Motor- and Cognitive-Related Brain Areas
por: Du, Xiao-Feng, et al.
Publicado: (2019)

Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study
por: D'Amico, Emanuele, et al.
Publicado: (2020)

Clinical Pathway for the Diagnosis and Management of Patients With Relapsing–Remitting Multiple Sclerosis: A First Proposal for the Peruvian Population
por: Caparó-Zamalloa, César, et al.
Publicado: (2021)

Assessing Lumbar Plexus and Sciatic Nerve Damage in Relapsing-Remitting Multiple Sclerosis Using Magnetisation Transfer Ratio
por: Boonsuth, Ratthaporn, et al.
Publicado: (2021)

Relaxation-Compensated Chemical Exchange Saturation Transfer MRI in the Brain at 7T: Application in Relapsing-Remitting Multiple Sclerosis
por: O'Grady, Kristin P., et al.
Publicado: (2022)

FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosis
por: Kearns, Patrick K A, et al.
Publicado: (2022)

Functional Connectivity Alterations Reveal Complex Mechanisms Based on Clinical and Radiological Status in Mild Relapsing Remitting Multiple Sclerosis
por: Castellazzi, Gloria, et al.
Publicado: (2018)

Impact of Repetitive Transcranial Magnetic Stimulation on Neurocognition and Oxidative Stress in Relapsing-Remitting Multiple Sclerosis: A Case Report
por: Agüera, Eduardo, et al.
Publicado: (2020)

Assessing ‘no evidence of disease activity’ status in patients with relapsing–remitting multiple sclerosis: a long-term follow-up
por: Zilli, Chiara, et al.
Publicado: (2023)

Physical activity is related to disease severity and fatigue, but not to relapse rate in persons with relapsing remitting multiple sclerosis – a self-reported questionnaire based study
por: Schlagheck, Marit L., et al.
Publicado: (2023)

Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies
por: Nakamura, Kunio, et al.
Publicado: (2022)

Investigating Serum sHLA-G Cooperation With MRI Activity and Disease-Modifying Treatment Outcome in Relapsing-Remitting Multiple Sclerosis
por: Amoriello, Roberta, et al.
Publicado: (2022)

Multimodal diagnostics in multiple sclerosis: predicting disability and conversion from relapsing-remitting to secondary progressive disease course – protocol for systematic review and meta-analysis
por: Statsenko, Yauhen, et al.
Publicado: (2023)

Association Between Serum Vitamin D Levels and Frequency of Relapses in Patients With Multiple Sclerosis
por: Mansoor, Farah, et al.
Publicado: (2021)

Intestinal Permeability and Circulating CD161+CCR6+CD8+T Cells in Patients With Relapsing–Remitting Multiple Sclerosis Treated With Dimethylfumarate
por: Buscarinu, Maria C., et al.
Publicado: (2021)

The role of autoimmune antibodies to predict secondary autoimmunity in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab: A nationwide prospective survey
por: Sandgren, Sofia, et al.
Publicado: (2023)

Impact of depression and fatigue on relapsing remitting multiple sclerosis in Kingdom of Saudi Arabia
por: Alshamrani, Foziah J., et al.
Publicado: (2020)

Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center
por: Boziki, Marina, et al.
Publicado: (2021)

Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits
por: Thöne, Jan, et al.
Publicado: (2013)

Postural Control in Relapsing-Remitting Multiple Sclerosis
por: Cusin, Flavia Salvaterra, et al.
Publicado: (2022)

Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study
por: Butzkueven, Helmut, et al.
Publicado: (2020)

Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry
por: Braune, Stefan, et al.
Publicado: (2021)

Dravet Syndrome: An Overview
por: Anwar, Arsalan, et al.
Publicado: (2019)

Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience
por: Zanghì, Aurora, et al.
Publicado: (2020)

Impact of disease-modifying therapies on MRI and neurocognitive outcomes in relapsing–remitting multiple sclerosis: a protocol for a systematic review and network meta-analysis
por: Lees, Samuel, et al.
Publicado: (2021)

Review of daclizumab and its therapeutic potential in the treatment of relapsing–remitting multiple sclerosis
por: Reardon, Jennifer, et al.
Publicado: (2013)

Expanding the Potential Therapeutic Options for Remote Ischemic Preconditioning: Use in Multiple Sclerosis
por: Camara-Lemarroy, Carlos R., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_urgim09mf41a6abosp6i44k35s